PNC-27 regulatory status
Current status of PNC-27 in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of PNC-27?
Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 29, 2026
- FDA and compounding
- PNC-27 is not an FDA approved drug and is not part of any approved drug. As of the last verification date it does not appear in any FDA 503A category or on the list of withdrawn nominations, and it is not on the 503A bulks list, so a 503A pharmacy has no federal basis to compound it from bulk. FDA has described PNC-27 as an unapproved drug product promoted as a treatment or cure for cancer, and in January 2017 an FDA laboratory found bacterial contamination in a PNC-27 sample.
- WADA
- WADA prohibited
- Access path
- Not legally available for human use in the United States.
- No registered clinical trial is recruiting as of the last verified date.
- Products sold online are unapproved and FDA has specifically warned against them.
Full PNC-27 page: evidence, dosing in the literature, and sources
How has the status of PNC-27 changed over time?
No dated regulatory event has been recorded for PNC-27. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for PNC-27 and the source of each dated event.